Monte Rosa Therapeutics
Monte Rosa Therapeutics Inc is an American clinical-stage biotechnology company developing targeted protein degradation (TPD) therapeutics using its proprietary QuPAD platform. The company designs molecular glue degraders that selectively recruit E3 ligases to degrade disease-causing proteins, advancing clinical candidates including MRT-2359 targeting GSPT1 for MYC-driven solid tumors and lung cancers, alongside MRT-6160 targeting VAV1 for autoimmune diseases. Principal revenue is driven through research collaboration milestone payments, licensing agreements, and capital raises prior to commercial authorization. Core end markets encompass clinical oncology research centers, immunology hospital departments, and targeted prescription patients globally. Monte Rosa Therapeutics holds an innovative pioneer position in the biopharmaceutical sector for AI-driven molecular glue protein degrader engineering. The corporation is headquartered in Boston, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
3 of the funds FundTelligence covers report a position in Monte Rosa Therapeutics.
- Legal name
- Monte Rosa Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Monte Rosa Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)